NFL Biosciences SA (FR:ALNFL) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
NFL Biosciences SA has made significant progress in the first half of 2024 with its smoking cessation drug NFL-101, successfully completing Phase 2 trials and preparing for Phase 3, showing comparable efficacy to Champix without the side effects. The company also raised €3 million through a capital increase and is working on co-developing NFL-301, a treatment for excessive alcohol consumption, with plans aligned with FDA guidance. With these developments, NFL Biosciences extends its cash runway to the third quarter of 2025.
For further insights into FR:ALNFL stock, check out TipRanks’ Stock Analysis page.